HC Wainwright Reiterates Buy Rating on SAB Biotherapeutics

HC Wainwright maintains its positive outlook on SAB Biotherapeutics with a $10 price target.

Written by EarningsIQ · Published Jun 16, 2026, 2:05 AM EDT · Updated Jun 16, 2026, 2:01 PM EDT

Key Points

HC Wainwright reiterated its buy rating on SAB Biotherapeutics, Inc. (SABS) on June 15, 2026, with a price target of $10.
Shares of SAB Biotherapeutics are trading around $3.33, with a market cap of about $298.2 million and a 52-week range between $1.65 and $6.60.
Institutional activity includes Perceptive Advisors adding 5,628,533 shares, now holding 6,431,743 shares valued at $24.6 million.

On June 15, 2026, HC Wainwright reiterated its buy rating on SAB Biotherapeutics, Inc. (NasdaqCM: SABS), maintaining a price target of $10. This comes as shares of the biotechnology company are trading around $3.33.

SAB Biotherapeutics Stock Snapshot

Shares of NasdaqCM:SABS traded near $3.33 recently. SAB Biotherapeutics has a market cap of approximately $298.2 million. The stock has seen a 52-week low of $1.65 and a high of $6.60. Its 50-day moving average is $3.69, while the 200-day moving average is $3.48. The company has a strong liquidity position with a current ratio of 11.45 and a quick ratio of 11.06, although it carries some leverage with a debt-to-equity ratio of 2.72.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright & Co. reiterated its buy rating on SAB Biotherapeutics with a $10 price target. On the same day, Leerink Partners maintained their buy rating with a $12 target. Earlier, on May 22, 2026, Citigroup initiated coverage with a buy rating and an $11 target, while Jefferies did the same on May 20, 2026, also with an $11 target. The consensus among analysts is a strong buy, with a mean price target of $10.6 based on 10 opinions.

Other Institutional Activity in SAB Biotherapeutics

Among institutional investors, Perceptive Advisors LLC significantly increased its position by adding 5,628,533 shares, bringing its total to 6,431,743 shares valued at about $24.6 million. Similarly, Balyasny Asset Management L.P. boosted its holdings by 3,285,000 shares, now holding 3,760,439 shares worth roughly $14.4 million. Meanwhile, VIVO Capital, LLC maintained its position with 11,420,000 shares valued at approximately $43.7 million.

Insider Buying and Selling at SAB Biotherapeutics, Inc.

Recent insider activity includes several notable transactions. On February 3, 2026, CEO Samuel Reich acquired 4,800,000 shares, while Chief Financial Officer Lucy To bought 2,400,000 shares. Chief Operating Officer Christoph Lawrence Bausch and Chief Medical Officer Alexandra Kropotova each purchased 1,800,000 and 2,400,000 shares, respectively. These transactions were not part of a pre-planned trading program.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company based in Miami Beach, Florida. It focuses on developing human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. Its lead product candidate, SAB-142, is in Phase 2b clinical trials for treating autoimmune type 1 diabetes. Founded in 2014, the company is led by CEO Samuel J. Reich and has about 86 employees.

Bottom Line

SAB Biotherapeutics continues to attract attention from analysts and institutional investors. HC Wainwright's reiterated buy rating and $10 price target underscore confidence in the company's prospects. Investors will be watching for upcoming developments, particularly as SAB advances its clinical trials. As always, remember that this analysis is based on past data and should not be construed as current investment advice.